Clara Allayous

1.2k total citations
31 papers, 208 citations indexed

About

Clara Allayous is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Clara Allayous has authored 31 papers receiving a total of 208 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 15 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Clara Allayous's work include Cancer Immunotherapy and Biomarkers (21 papers), CAR-T cell therapy research (13 papers) and Melanoma and MAPK Pathways (13 papers). Clara Allayous is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), CAR-T cell therapy research (13 papers) and Melanoma and MAPK Pathways (13 papers). Clara Allayous collaborates with scholars based in France, United States and Australia. Clara Allayous's co-authors include Célèste Lebbé, Barouyr Baroudjian, Matteo S. Carlino, Douglas B. Johnson, Julie Delyon, Georgina V. Long, Lauren Brown, Shahneen Sandhu, Patrick A. Ott and Alison M. Weppler and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of the American Academy of Dermatology.

In The Last Decade

Clara Allayous

31 papers receiving 206 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Clara Allayous France	8	169	76	41	41	23	31	208
Hartmut Kristeleit United Kingdom	7	119 0.7×	88 1.2×	69 1.7×	33 0.8×	40 1.7×	19	229
Lorenzo Ruggieri Italy	6	244 1.4×	75 1.0×	98 2.4×	46 1.1×	39 1.7×	14	310
Dina Sakaeva Russia	9	165 1.0×	96 1.3×	88 2.1×	28 0.7×	15 0.7×	44	267
Luca Paruzzo Italy	6	99 0.6×	71 0.9×	33 0.8×	47 1.1×	18 0.8×	12	192
Ashish Noronha Israel	7	95 0.6×	126 1.7×	66 1.6×	16 0.4×	11 0.5×	11	208
Ricardo Martínez United States	8	103 0.6×	141 1.9×	52 1.3×	13 0.3×	17 0.7×	15	235
Hengyu Lu United States	8	111 0.7×	158 2.1×	55 1.3×	52 1.3×	10 0.4×	11	269
David König Switzerland	7	145 0.9×	83 1.1×	95 2.3×	65 1.6×	14 0.6×	26	247
Eisuke Kurihara Japan	8	148 0.9×	110 1.4×	113 2.8×	23 0.6×	9 0.4×	12	271
J A P Spijkers-Hagelstein Netherlands	7	55 0.3×	150 2.0×	25 0.6×	54 1.3×	28 1.2×	9	293

Countries citing papers authored by Clara Allayous

Since Specialization

Citations

This map shows the geographic impact of Clara Allayous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clara Allayous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clara Allayous more than expected).

Fields of papers citing papers by Clara Allayous

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clara Allayous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clara Allayous. The network helps show where Clara Allayous may publish in the future.

Co-authorship network of co-authors of Clara Allayous

This figure shows the co-authorship network connecting the top 25 collaborators of Clara Allayous. A scholar is included among the top collaborators of Clara Allayous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clara Allayous. Clara Allayous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilhelm, Claire, Célèste Lebbé, Mohammed I. Y. Elmallah, et al.. (2024). PROM2 overexpression induces metastatic potential through epithelial‐to‐mesenchymal transition and ferroptosis resistance in human cancers. Clinical and Translational Medicine. 14(3). e1632–e1632. 10 indexed citations

Lai‐Kwon, Julia, Matteo S. Carlino, Naima Benannoune, et al.. (2023). Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma. European Journal of Cancer. 186. 12–21. 1 indexed citations

Russo, David, Stéphane Dalle, O. Dereure, et al.. (2023). Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase). Frontiers in Oncology. 13. 1250026–1250026. 4 indexed citations

Kuijpers, Anke, Firas Kreidieh, Teresa Amaral, et al.. (2023). Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9518–9518. 3 indexed citations

Silva, Inês Pires da, Tasnia Ahmed, Florentia Dimitriou, et al.. (2022). Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for ImmunoTherapy of Cancer. 10(7). e004610–e004610. 15 indexed citations

Carlino, Matteo S., Naima Benannoune, Caroline Robert, et al.. (2022). Efficacy of ipilimumab 3mg/kg following progression on low dose ipilimumab in metastatic melanoma.. Journal of Clinical Oncology. 40(16_suppl). e21533–e21533. 1 indexed citations

Rousset, Perrine, Stéphane Dalle, Laurent Mortier, et al.. (2022). Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort. Journal of the American Academy of Dermatology. 88(4). 808–815. 3 indexed citations

Goldwirt, Lauriane, Baptiste Louveau, Barouyr Baroudjian, et al.. (2021). Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic–pharmacodynamic real-life study. Cancer Chemotherapy and Pharmacology. 88(3). 427–437. 6 indexed citations

Dimitriou, Florentia, Anne Zaremba, Clara Allayous, et al.. (2021). Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. European Journal of Cancer. 149. 37–48. 17 indexed citations

10.

Dalle, Stéphane, M.‐T. Leccia, Laurent Mortier, et al.. (2021). Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort. Journal of the American Academy of Dermatology. 86(2). 345–352. 8 indexed citations

11.

Silva, Inês Pires da, Judith M. Versluis, Tasnia Ahmed, et al.. (2021). Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.. Journal of Clinical Oncology. 39(15_suppl). 9533–9533. 1 indexed citations

12.

Brown, Lauren, Alison M. Weppler, Prachi Bhave, et al.. (2021). Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. Journal for ImmunoTherapy of Cancer. 9(5). e002121–e002121. 45 indexed citations

13.

Versluis, Judith M., Alison M. Weppler, Lauren Brown, et al.. (2020). 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition. Annals of Oncology. 31. S733–S734. 1 indexed citations

14.

Nardin, Charlée, Stéphane Dalle, M.‐T. Leccia, et al.. (2020). Long-term immune-related adverse events under PD-1 inhibitors: a multicenter prospective cohort study (MELBASE).. Journal of Clinical Oncology. 38(15_suppl). 10057–10057. 2 indexed citations

15.

Brown, Lauren, Alison M. Weppler, Prachi Bhave, et al.. (2020). Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).. Journal of Clinical Oncology. 38(15_suppl). 10026–10026. 3 indexed citations

16.

Gauci, Marie-Léa, Barouyr Baroudjian, Julie Delyon, et al.. (2020). Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. Clinics and Research in Hepatology and Gastroenterology. 45(2). 101491–101491. 25 indexed citations

17.

Gauci, Marie-Léa, Philippe Boudou, Julie Delyon, et al.. (2019). Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. Melanoma Research. 29(3). 328–332. 6 indexed citations

18.

Allayous, Clara, Stéphane Dalle, Philippe Saïag, et al.. (2015). Follow-up of a French national cohort of melanoma stage IV and unresectable stage III patients, MelBase.. Journal of Clinical Oncology. 33(15_suppl). e20113–e20113. 1 indexed citations

19.

Allayous, Clara, Laetitia Da Meda, Joëlle Bénessiano, et al.. (2014). MelBase, constitution et suivi d’une cohorte nationale de patients atteints de mélanome stade III inopérable ou stade IV avec collection d’une base de données clinico-biologiques. Annales de Dermatologie et de Vénéréologie. 141(12). S396–S396. 2 indexed citations

20.

Allayous, Clara, et al.. (2007). VELOCITY ALLOWED RED BLOOD CELL CLASSIFICATION. IFAC Proceedings Volumes. 40(4). 375–380. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact